ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2017
[Deep Anterior Lamellar Keratoplasty : Experiences and results of the first 100 consecutive DALK from the University Eye Hospital of Cologne].
Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 19 citations in OpenAlex.
- Outcomes of deep anterior lamellar keratoplasty and penetrating keratoplasty in keratoconic eyes with and without previous hydrops.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Current Perspectives on Corneal Transplantation.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Outcome of deep anterior lamellar keratoplasty patients with intraoperative Descemet's membrane perforation: A retrospective cross-sectional study.Indian journal of ophthalmology · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeep anterior lamellar keratoplasty (DALK) is a treatment option for patients with diseases of the corneal stroma without endothelial involvement and has been used at the Department of Ophthalmology of the University of Cologne since July 2011. Experiences and results of the first 100 consecutive cases from Cologne with a minimum follow-up of 1 year are summarized. MATERIALS AND
methodsWe included the first 100 consecutive DALKs. Indications for anterior lamellar keratoplasty, the feasibility of the surgery, the postoperative course, in addition to the complications and clinical outcome 3 months after complete suture removal, were examined. The rate of conversion to penetrating keratoplasty in all planned DALKs during the observation period was also recorded. Mean follow-up was 25.6 ± 13 months.
resultsIn 99 eyes of 97 patients (72 men, 25 women; aged 43.5 ± 16.9 years), the first 100 DALKs were performed in the period between 26 July 2011 and 27 January 2015 (87 cases electively, 13 cases as DALK à chaud, 1 of which was a second DALK). The most common indications were keratoconus (68%), corneal ulcers (13%), and corneal scarring (13%). On average, visual acuity increased from 0.83 ± 0.4 to 0.09 ± 0.1 logMAR. In 6 eyes (6%) grafts could not be preserved because of a corneal ulcer (n = 5, n = 3 of which were recurrent episodes), and in 1 case because of postoperative bulbus trauma. Rate of conversion to penetrating keratoplasty during the observation period was 11.5%. In eyes with keratoconus, visual acuity increased from 0.89 ± 0.4 before DALK to 0.06 ± 0.1 logMAR (best-corrected with contact lens) and the conversion rate was 17.6%.
conclusionDALK represents a reliable technique for corneal transplantation in different pathological conditions of the cornea and the risk of endothelial immune responses can be avoided completely. In keratoconus and corneal scarring in particular, DALK can be used as a safe treatment option with very good results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.